Clinical Notes AI's AI-powered platform uses over 25 different AI models to generate highly complex behavioral healthcare ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Technological innovation has ...

Historically, medical research has been male-dominated in terms of subjects as well as researchers, even though women make up ...

The company's CEO, James Dentzer, expressed optimism about the progress of Curis's clinical programs and the ... emavusertib. In terms of analyst ratings, H.C. Wainwright adjusted its outlook ...

There are benefits and risks to every potential path forward, in terms of outcomes, unintended consequences of treatment ... One is to try to find all of the related information that exists in ...

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

While welcoming these positive changes, the CPT reiterates its recommendations to improve the screening for injuries at ...

Yaron Werber has given his Buy rating due to a combination of factors, primarily the promising progress and outcomes of IO Biotech’s clinical trials. The company’s Phase 3 melanoma study is on ...

In its third quarter of 2024 financial report, Tyra Biosciences highlighted significant progress in its clinical trials and corporate development. The company reported positive interim results for ...

Tyra Bioscience, Inc ( (TYRA)) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors. Tyra Biosciences, Inc. is a clinical-stage ...

Medical Properties Trust has made progress with liquidity but faces rising debt and asset write-downs. Learn why MPW stock ...